Mitral regurgitation:
Treatment is complex and options are limited
Treatment is complex and options are limited
Mitral regurgitation (MR) occurs in approximately 2% of the population, with up to 10% of people over 75 years old affected1
Medically managed patients with severe MR have poor outcomes2
Transform the way you see mitral valve repair
Empowering
Optimised leaflet
capture
- Empowering delivery system with direct manoeuvring in 3 planes
- Independent leaflet capture
Effective
Designed for effective MR
reduction
- Broad paddles maximize leaflet coaptation
- Central spacer fills the regurgitant orifice area
Safe
Excellent safety
profile
- Spacer & contoured paddle design reduce stress on leaflets
- Implant elongation helps promote safe subvalvular manoeuvring
Optimised leaflet capture
Empowering PASCAL delivery system with direct manoeuvring in 3 planes to improve procedural efficiency
Broad paddles create a wide area for simplified leaflet capture
Independent leaflet capture supports gentle interaction and enables operators to capture leaflets in difficult pathologies
Designed for effective mitral regurgitation reduction3
Configuration delivers desired outcomes while respecting native anatomy
Excellent safety profile
Contoured paddles and a unique central spacer are designed to reduce leaflet stress while implant elongation helps promote safe subvalvular manoeuvring
See how it works
Watch the PASCAL repair system procedural animation
Learn more about Edwards' transcatheter mitral
and tricuspid portfolio
and tricuspid portfolio
References:
- Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-1011.
- Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol. 2014;63:185-186.
- Praz F, Spargias K, Chrissoheris M et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet. 2017;390(10096):773-780.
Content relating to Edwards Lifesciences devices is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed, or click Decline to view non-device related content.